JP2020138981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020138981A5 JP2020138981A5 JP2020100961A JP2020100961A JP2020138981A5 JP 2020138981 A5 JP2020138981 A5 JP 2020138981A5 JP 2020100961 A JP2020100961 A JP 2020100961A JP 2020100961 A JP2020100961 A JP 2020100961A JP 2020138981 A5 JP2020138981 A5 JP 2020138981A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- preparation according
- concentration
- antibody
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023030012A JP2023060016A (ja) | 2017-03-01 | 2023-02-28 | モノクローナル抗体製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465269P | 2017-03-01 | 2017-03-01 | |
| US62/465,269 | 2017-03-01 | ||
| JP2019547137A JP2020509025A (ja) | 2017-03-01 | 2018-02-28 | モノクローナル抗体製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547137A Division JP2020509025A (ja) | 2017-03-01 | 2018-02-28 | モノクローナル抗体製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030012A Division JP2023060016A (ja) | 2017-03-01 | 2023-02-28 | モノクローナル抗体製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020138981A JP2020138981A (ja) | 2020-09-03 |
| JP2020138981A5 true JP2020138981A5 (https=) | 2021-02-25 |
| JP7590125B2 JP7590125B2 (ja) | 2024-11-26 |
Family
ID=61868490
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547137A Pending JP2020509025A (ja) | 2017-03-01 | 2018-02-28 | モノクローナル抗体製剤 |
| JP2020100961A Active JP7590125B2 (ja) | 2017-03-01 | 2020-06-10 | モノクローナル抗体製剤 |
| JP2023030012A Pending JP2023060016A (ja) | 2017-03-01 | 2023-02-28 | モノクローナル抗体製剤 |
| JP2023034558A Pending JP2023071916A (ja) | 2017-03-01 | 2023-03-07 | モノクローナル抗体製剤 |
| JP2025014959A Pending JP2025072446A (ja) | 2017-03-01 | 2025-01-31 | モノクローナル抗体製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547137A Pending JP2020509025A (ja) | 2017-03-01 | 2018-02-28 | モノクローナル抗体製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030012A Pending JP2023060016A (ja) | 2017-03-01 | 2023-02-28 | モノクローナル抗体製剤 |
| JP2023034558A Pending JP2023071916A (ja) | 2017-03-01 | 2023-03-07 | モノクローナル抗体製剤 |
| JP2025014959A Pending JP2025072446A (ja) | 2017-03-01 | 2025-01-31 | モノクローナル抗体製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20200283516A1 (https=) |
| EP (2) | EP3797792A1 (https=) |
| JP (5) | JP2020509025A (https=) |
| KR (1) | KR102589598B1 (https=) |
| CN (2) | CN112057419B (https=) |
| AU (2) | AU2018227036B2 (https=) |
| BR (1) | BR112019018022A2 (https=) |
| CA (2) | CA3054386A1 (https=) |
| MX (1) | MX2019010282A (https=) |
| WO (1) | WO2018158332A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| SI3456743T1 (sl) | 2013-05-30 | 2022-01-31 | Kiniksa Pharmaceuticals, Ltd. | Proteini, ki vežejo antigen receptorja onkostatina M |
| BR112016013347B1 (pt) | 2013-12-26 | 2023-12-12 | Mitsubishi Tanabe Pharma Corporation | Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos |
| EP4353316A3 (en) | 2014-01-15 | 2024-08-21 | Medimmune Limited | Rsv-specific antibodies and functional parts thereof |
| CN106715473B (zh) | 2014-10-01 | 2021-11-23 | 免疫医疗有限公司 | 替格瑞洛的抗体及其使用方法 |
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| JP7398958B2 (ja) | 2017-04-11 | 2023-12-15 | キニクサ ファーマシューティカルズ， リミテッド | 安定的抗ｏｓｍｒ抗体製剤 |
| AU2018263868A1 (en) | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| MY199245A (en) | 2017-08-31 | 2023-10-23 | Hyogo College Medicine | Il-33 antagonist-containing therapeutic agent for endometriosis |
| JP7407723B2 (ja) * | 2018-09-14 | 2024-01-04 | 田辺三菱製薬株式会社 | ヒト抗ｉｌ－３３モノクローナル抗体含有医薬用組成物 |
| PL3852617T3 (pl) * | 2018-09-20 | 2026-01-26 | SFJ Pharma X, Inc. | Zastosowanie fragmentów przeciwciała do odwrócenia aktywności tikagreloru |
| KR102885113B1 (ko) | 2018-10-18 | 2025-11-13 | 머크 샤프 앤드 돔 엘엘씨 | 항-rsv 항체의 제제 및 그의 사용 방법 |
| CN120842406A (zh) | 2018-10-31 | 2025-10-28 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| CN113316458B (zh) | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| US12024553B2 (en) * | 2019-04-30 | 2024-07-02 | Medimmune Limited | Dosage regimens for and compositions including anti-RSV antibodies |
| CN115298313B (zh) * | 2020-03-17 | 2025-10-24 | Xbrane生物制药公司 | 用于表达重组蛋白的tis序列和信号肽序列的新组合 |
| JP2023534576A (ja) | 2020-03-23 | 2023-08-10 | メドイミューン・リミテッド | アトピー性皮膚炎及び関連する障害の治療方法 |
| US12187788B2 (en) | 2020-03-23 | 2025-01-07 | Medimmune Limited | Methods for treating atopic dermatitis and related disorders |
| PE20230116A1 (es) * | 2020-04-06 | 2023-01-27 | Univ Leland Stanford Junior | Formulacion de anticuerpos |
| KR20230010239A (ko) * | 2020-05-11 | 2023-01-18 | 메디뮨 리미티드 | 항-il-33 항체의 제형물 |
| GB202108379D0 (en) | 2021-06-11 | 2021-07-28 | Medlmmune Ltd | Methods for treating a topic dermatitis and related disorders |
| JP2024531300A (ja) | 2021-08-16 | 2024-08-29 | メディミューン，エルエルシー | 抗ｉｌ－１３抗体製剤 |
| US20240400669A1 (en) | 2021-09-28 | 2024-12-05 | Medimmune Limited | Methods for treating atopic dermatitis and related disorders |
| WO2024114735A1 (en) * | 2022-12-01 | 2024-06-06 | I-Mab Biopharma (Hangzhou) Co., Ltd. | Liquid pharmaceutical formulation of anti-gm-csf antibody and uses thereof |
| KR20250156121A (ko) | 2023-03-16 | 2025-10-31 | 오노 야꾸힝 고교 가부시키가이샤 | 항체 제제 |
| WO2024190892A1 (ja) | 2023-03-16 | 2024-09-19 | 小野薬品工業株式会社 | 抗体製剤 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PL1999152T3 (pl) * | 2006-03-27 | 2013-05-31 | Medimmune Ltd | Element wiążący receptor GM-CSF |
| CN101541345A (zh) * | 2006-09-25 | 2009-09-23 | 米迪缪尼有限公司 | 稳定化的抗体制剂和其应用 |
| CA2674608A1 (en) | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
| CA2696049A1 (en) | 2007-08-17 | 2009-02-26 | Amgen Inc. | Formulations of antibodies and fc-fusion molecules using polycations |
| JP4885308B2 (ja) * | 2009-03-19 | 2012-02-29 | 中外製薬株式会社 | 改良された抗体分子を含有する製剤 |
| AR080428A1 (es) * | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| US9956165B2 (en) * | 2010-03-01 | 2018-05-01 | Cytodyn Inc. | Concentrated protein formulations and uses thereof |
| MX2013004212A (es) * | 2010-10-15 | 2013-09-02 | Medimmune Ltd | Terapias para mejorar la funcion pulmonar. |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| JP6265970B2 (ja) | 2012-03-26 | 2018-01-24 | サノフイ | 安定なＩｇＧ４に基づく結合剤の製剤 |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| US20150239970A1 (en) * | 2012-10-25 | 2015-08-27 | Medimmune, Llc | Stable, Low Viscosity Antibody Formulation |
| AR093297A1 (es) * | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| KR20170065662A (ko) * | 2014-10-18 | 2017-06-13 | 화이자 인코포레이티드 | 항-il-7r 항체 조성물 |
| TWI761453B (zh) * | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
-
2018
- 2018-02-28 BR BR112019018022-2A patent/BR112019018022A2/pt unknown
- 2018-02-28 WO PCT/EP2018/054960 patent/WO2018158332A1/en not_active Ceased
- 2018-02-28 JP JP2019547137A patent/JP2020509025A/ja active Pending
- 2018-02-28 US US16/488,302 patent/US20200283516A1/en not_active Abandoned
- 2018-02-28 MX MX2019010282A patent/MX2019010282A/es unknown
- 2018-02-28 CA CA3054386A patent/CA3054386A1/en active Pending
- 2018-02-28 CN CN202010229368.0A patent/CN112057419B/zh active Active
- 2018-02-28 CN CN201880014493.0A patent/CN110366429B/zh active Active
- 2018-02-28 EP EP20190885.2A patent/EP3797792A1/en active Pending
- 2018-02-28 KR KR1020197028472A patent/KR102589598B1/ko active Active
- 2018-02-28 EP EP18714973.7A patent/EP3589318A1/en active Pending
- 2018-02-28 CA CA3235178A patent/CA3235178A1/en active Pending
- 2018-02-28 AU AU2018227036A patent/AU2018227036B2/en active Active
-
2020
- 2020-06-10 JP JP2020100961A patent/JP7590125B2/ja active Active
-
2021
- 2021-04-07 US US17/224,900 patent/US20220089713A1/en not_active Abandoned
- 2021-09-29 AU AU2021240216A patent/AU2021240216A1/en not_active Abandoned
- 2021-11-19 US US17/455,713 patent/US20220204597A1/en not_active Abandoned
-
2023
- 2023-02-28 JP JP2023030012A patent/JP2023060016A/ja active Pending
- 2023-03-07 JP JP2023034558A patent/JP2023071916A/ja active Pending
-
2024
- 2024-05-28 US US18/676,425 patent/US20250163142A1/en active Pending
- 2024-12-10 US US18/976,239 patent/US20250333493A1/en active Pending
-
2025
- 2025-01-31 JP JP2025014959A patent/JP2025072446A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020138981A5 (https=) | ||
| JP6416841B2 (ja) | 医薬製剤 | |
| JP7473603B2 (ja) | 液体医薬組成物 | |
| AU2015342815B2 (en) | Stable protein solution formulation containing high concentration of an anti-VEGF antibody | |
| JP7046088B2 (ja) | 抗ｒｓｖモノクローナル抗体製剤 | |
| JP2020518599A5 (https=) | ||
| TWI857996B (zh) | 含高濃度抗ｖｅｇｆ抗體之蛋白質溶液配製物 | |
| JP2013500947A5 (https=) | ||
| JP2024160287A5 (https=) | ||
| JP2019509311A5 (https=) | ||
| JP2018076350A5 (https=) | ||
| JP2020509031A5 (https=) | ||
| JP2013543505A5 (https=) | ||
| JP2019504086A5 (https=) | ||
| JP2020532562A5 (https=) | ||
| WO2019055357A1 (en) | METHOD FOR THE LYOPHILIZED PHARMACEUTICAL FORMULATION OF A THERAPEUTIC PROTEIN | |
| JP2019501920A5 (https=) | ||
| JP2020511443A5 (https=) | ||
| CN109952093A (zh) | 一种sost抗体药物组合物及其用途 | |
| JP2021501213A5 (https=) | ||
| CN111683681A (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
| JP2021533149A5 (https=) | ||
| CN116077650A (zh) | 一种稳定的新冠中和抗体的药物组合物及其应用 | |
| RU2025121573A (ru) | Стабильные белковые композиции антитела к pd1 | |
| WO2022265591A1 (en) | Pharmaceutical compositions of bevacizumab |